Triple Point Biologics' Metalloproteinases antibody catalog covers the full zinc-dependent endopeptidase superfamily, including MMP-1 through MMP-28, the membrane-type MMPs (MT1- through MT6-MMP), ADAM10, ADAM17/TACE, and a broad range of ADAMTS family members. Metalloproteinases share a conserved catalytic domain containing the HExxHxxGxxH zinc-binding motif and are defined functionally by their capacity to cleave extracellular matrix components, cell-surface proteins, and signaling precursors. The MMP subfamily degrades structural ECM constituents — collagens, fibronectin, laminin, and proteoglycans — while the ADAM and ADAMTS subfamilies mediate ectodomain shedding of transmembrane proteins and processing of soluble substrates such as von Willebrand factor (ADAMTS13) and aggrecan (ADAMTS4/5). Collectively, metalloproteinases regulate tissue remodeling, inflammation, tumor invasion and metastasis, and are among the most extensively studied protease targets in cancer biology, fibrosis, and vascular disease research.

Triple Point Biologics has produced antibodies against proteinases and their inhibitors since 1994. Each rabbit polyclonal in this catalog is raised against defined antigen regions — typically recombinant full-length protein or domain-specific fragments spanning the catalytic, hemopexin, disintegrin, or thrombospondin motif regions — selected to minimize cross-reactivity within the structurally homologous metalloproteinase superfamily. Antibodies are validated by Western blot and immunohistochemistry (IHC) on human and rodent tissue panels; immunofluorescence (IF) performance is noted per-entry where data are available. Cross-reactivity with related family members is characterized as validated or predicted based on sequence identity analysis and empirical testing, and is documented in each product datasheet. Every antibody target in this collection has a matched recombinant protein produced in the same laboratory, providing a structurally consistent positive control for assay development, titer determination, and standard curve construction. See the recombinant protein catalog and validation standards page for methodology details.

Antibodies in this collection are used in studies of ECM remodeling kinetics, tumor cell invasion assays, ectodomain shedding quantification, and substrate cleavage profiling. For researchers designing activity-based experiments, the protease activity assay guide outlines how antibody-based detection integrates with fluorogenic substrate and zymography workflows. The recombinant protein positive controls guide describes best practices for using matched recombinant proteins alongside antibody detection in Western blot and ELISA formats. For compound screening applications, the protease inhibitor screening guide covers antibody-based endpoint readouts compatible with MMP and ADAM inhibitor panels. Catalog entries include species reactivity data, recommended dilution ranges, and buffer conditions as determined by in-house testing.